StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > Took over 2 hrs

<< Previous

Bullboard Posts

Next >>

Comment by gojotv!on Jan 05, 2022 12:05pm

175 Views

Post# 34285517

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Took over 2 hrs

Then why is the answer "no" to the question "Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?"
Reading is fundamental.

LithLover wrote:

They did on Nov 26. This is just the SEC official filing of the recent private placement.

gojotv! wrote: If this is true, doesn't the company have to issue a news release? This would be material.

Nailbiter1 wrote: https://www.sec.gov/Archives/edgar/data/0001454263/000145426322000001/xslFormDX01/primary_doc.xml